Viagra patent expires in Europe

viagra patent expiry pfizer (Enrico Matteucci http://www.flickr.com/photos/enricomatteucci/2492418019/)The price of erectile dysfunction drug sildenafil looks set to tumble as Pfizer's patent on branded Viagra has expired in Europe. While the blue tablet remains under patent in the USA until 2020, the patent expiry in various European states opens the floodgates for generics into the erectile dysfunction market. The Financial Times reports that generic sildenafil will be allowed in nearly a dozen European markets, with manufacturers bracing themselves to deliver bulk quantities of the drug into the UK and other countries.

The price for a tablet could fall from roughly £6 to around £1 as large players in the generics arena, such as Teva, move in. However, rather than allow generics manufacturers free reign of the market, Pfizer is also reportedly introducing their own cheaper alternative (Financial Times) to be sold alongside branded Viagra.

Last year:

  • Viagra generated revenues of $2.05 billion worldwide
  • In the UK, 2.3 million prescriptions were written for the drug
  • Viagra cost the NHS £40 million

Read more at PharmaTimes >

What do you think? You can join our discussion on LinkedIn, or leave a comment below. Want more from Total BioPharma? Sign up to our newsletter – it doesn't cost anything and only takes a minute.

If you're interested in understanding the key market trends, policy updates, strategy and future environment for the generics sector, you might be be interested in attending World Generic Medicines Congress Americas 2013, 19-21 November 2013, Boston.

Leave a Reply

Your email address will not be published. Required fields are marked *